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Abstract
Background: Since November 2009, WHO recommends that adults infected with HIV should initiate antiretroviral therapy
(ART) at CD4+ cell counts of #350 cells/ml rather than #200 cells/ml. South Africa decided to adopt this strategy for
pregnant and TB co-infected patients only. We estimated the impact of fully adopting the new WHO guidelines on HIV
epidemic dynamics and associated costs.
Methods and Finding: We used an established model of the transmission and control of HIV in specified sexual networks
and healthcare settings. We quantified the model to represent Hlabisa subdistrict, KwaZulu-Natal, South Africa. We
predicted the HIV epidemic dynamics, number on ART and program costs under the new guidelines relative to treating
patients at #200 cells/ml for the next 30 years. During the first five years, the new WHO treatment guidelines require about
7% extra annual investments, whereas 28% more patients receive treatment. Furthermore, there will be a more profound
impact on HIV incidence, leading to relatively less annual costs after seven years. The resulting cumulative net costs reach a
break-even point after on average 16 years.
Conclusions: Our study strengthens the WHO recommendation of starting ART at #350 cells/ml for all HIV-infected patients.
Apart from the benefits associated with many life-years saved, a modest frontloading appears to lead to net savings within a
limited time-horizon. This finding is robust to alternative assumptions and foreseeable changes in ART prices and
effectiveness. Therefore, South Africa should aim at rapidly expanding its healthcare infrastructure to fully embrace the new
WHO guidelines.
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Introduction
WHO has recently (November 2009) adopted new guidelines calling
for earlier initiation of antiretroviral therapy (ART) for people infected
with HIV [1]. Under the old guidelines, patients with a CD4+ cell count
of #200 cells/ml were eligible to initiate ART. The revised guidelines
call for ART initiation when CD4+ cell counts fall to#350 cells/ml. In
April 2010 [2], South Africa adopted the new WHO treatment
guidelines for pregnant women and for patients with TB co-infection,
but decided at this time that the country could not expand the eligibility
to all patients as this would overburden the healthcare infrastructure.
For non-pregnant and non-TB HIV infected patients, the old strategy
of ART at CD4+ cell counts #200 cells/ml remains [3].
Little is known about what impact the new WHO treatment
guidelines will have on HIV epidemic dynamics and costs, especially
in the long run. On the one hand ART reduces mortality and
morbidity of the individual [4–6], and may reduce transmission of
HIV through the accompanying reduction in viral load and thus
infectivity [7–9]. On the other hand, longer survival of HIV patients
increases the duration of infectiousness. While initial costs of
adopting the new guidelines will be greater because of the increased
number of people now eligible for treatment, in the long run costs
may be saved because of the reduced number of new infections.
Moreover, the initial costs per patient are generally lower when
treatment is initiated earlier as patients require less additional care,
e.g. for treatment of opportunistic infections [10,11].
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Figure 1. Comparison of model predictions with data of the HIV-epidemic and ART rollout in Hlabisa subdistrict of the
Umkhanyakunde district in KwaZulu/Natal (KZN), South Africa. A. Modeled and actual demographic structure in 2006. Data derived from
Muhwava & Nyirenda [31]; B. Total number of partners in the last 12 months in men and women aged 20–49 years in the model versus total number
of reported partners derived from Todd et al [32] C. Modeled and observed prevalence of classic STIs in women aged 15–49 in KZN. Data derived from
White et al [33]. D. Modeled and actual HIV epidemic in KZN. Antenatal Care (ANC) data were adjusted by applying a 1:0.6 ratio of ANC prevalence
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With an estimated 5.7 million people living with HIV and an
overall HIV prevalence of 18% in adults, South Africa is home to
the largest population living with HIV in the world [12]. Within
South Africa, KwaZulu-Natal (KZN) is the most heavily affected
area, with prevalence rates in 2004 of about 24% for the adult
population, peaking at 51% in women aged 25–29 years [13,14].
The Africa Centre Demographic Information System (ACDIS)
contains high quality data on demography, sexual behavior, and
HIV status of about 85,000 people in the largely rural
Umkhanyakunde District of KZN [15]. ART rollout in this area
has expanded dramatically in the past years [16], with about 7,500
people initiating ART by end 2008 [17], and a substantial decline
in HIV-related and overall mortality [18].
In this paper we estimate the long-term impact of the full WHO
guidelines on the dynamics of the HIV epidemic and healthcare
costs in the Hlabisa subdistrict of Umkhanyakunde in KZN, South
Africa. We use STDSIM, an established microsimulation model
that simulates the spread of HIV and other STIs in a population of
individuals interacting through a network of sexual relationships
[19,20]. We quantify the potential net costs and life-years saved
due to the new WHO guidelines compared to treating patients at
#200 cells/ml.
Methods
Quantification of the model
We used data from ACDIS [15] and Hlabisa Treatment and
Care Programme [16] to represent demography, sexual risk
behavior, and the ART rollout in the Hlabisa subdistrict. A
detailed description of the model, quantifications, and data used
can be found in the Supplementary Material S1.
In the model, HIV patients are put on ART when they seek
care and their CD4+ cell counts are at a given threshold (#200 or
#350 cells/ml). We assumed ART to decrease infectivity by 92%
[7,21,22]. The survival on ART was assumed to be three times the
ART naı¨ve survival [6]. Health seeking behavior was fitted such
that the modeled CD4+ cell count at the first test accurately
reflects data from the Hlabisa Treatment and Care Programme
[16]. We assumed a dropout rate (proportion of patients on ART
stopping treatment permanently) of 1.27% per year, reflecting 5%
of patients lost to follow-up after four years, as reported by
Houlihan et al [16]. The ART component of the model is
illustrated in Supporting Figure 1 in Supplementary Material S1.
In the model, ART is introduced in 2004, and rolled-out in
accordance with the actual rollout among the 17 primary care
clinics in Hlabisa subdistrict.
Costs
We analyzed costs from the perspective of the Hlabisa
Treatment and Care Programme. In the absence of detailed local
data, we used published data from the public sector ART
programs in Cape Town, South Africa, consisting of ART costs
stratified by CD4+ cell count at initiation and number of years on
treatment (table 1) [10,23].Cost values reported in these studies
include costs for ART provision, treatment of opportunistic
infections, outpatient visits, and inpatient days -, and consist of
costs for equipment, medication, wages of healthcare personnel,
logistics and infrastructure. We excluded non-healthcare costs,
such as patient time and lost wages. Costs of patients on ART were
stratified by CD4+ count at initiation, which reflects the fact that
patients who start treatment at lower CD4+ counts are sicker and
therefore in need of additional health resources (inpatient and
outpatient visits, and non-ART medication). This increased
medical cost of starting at a lower CD4+ cell count is most
prominent in the first year of ART, and decreases in subsequent
years [10]. We assumed this difference to disappear after three
years. In addition, we added a one-time pre-ART cost, reflecting
the cost of care surrounding treatment initiation [10]. For patients
seeking care with CD4+ cell counts between 201 and 350 cells/ml
and not eligible for treatment, we included costs for HIV testing
and treatment for opportunistic infections [23]. For patients testing
with CD4+ cell counts of .350 cells/ml, we only assumed annual
costs for CD4+ monitoring [10]. Finally, we added a one-time cost
of dying (hospitalization prior to death) for all HIV-related deaths,
irrespective of ART status or CD4+ count at ART initiation [10].
ART costs were updated to reflect present ART price levels
[24]. All other costs were standardized to January 2010 prices
using South Africa’s consumer price index [25]. We then
Table 1. Overview of costs input values used in this study.
CD4+ count (cells/ml) at ART initiation Per patient annual ART costs (US$)
Pre-ART First year Second and third year Subsequent years
0–100 495 3,664 1,435 1,095
101–200 495 3,060 1,284 1,095
201–350 495 2,304 1,095 1,095
The perspective of the Hlabisa Treatment and Care Programme was chosen. Costs are stratified by CD4+ count at antiretroviral therapy (ART) initiation, and include
costs of diagnostic testing, ART provision, treatment of opportunistic infections, outpatient visits, and inpatient days. In addition, some costs were included for patients
seeking care but not (yet) eligible for ART: (1) 1,165 US$ per year for patients with CD4+ counts of 201–350 cells/ml, reflecting costs of testing and treatment of
opportunistic infections; and (2) 104 US$ for patients with CD4+ cell counts of .350 cells/ml reflecting costs of CD4+ cell count monitoring. Furthermore, a one-time
cost of dying of 1,197 US$ was included for each HIV-related death, irrespective of being on treatment and CD4+ count at initiation.
doi:10.1371/journal.pone.0021919.t001
versus Africa Centre (AC) prevalence in 2004 to all data points. ANC data derived from UNAIDS [12], AC data from Ba¨rnighausen et al [13]. Prevalence
in 2005–2009 is from unpublished ACDIS sero-surveillance data (age specific data, adjusted for population age-structure). Dotted lines represent the
predicted HIV-prevalence when assuming a 10% increase and 10% decrease in the assumed overall partner change rate (‘promiscuity factor’). The
latter roughly reflects the HIV epidemic of South Africa as a whole (prevalence of 18% in 2004) E. Modeled and actual age- and sex-specific HIV
prevalence in 2004. Data derived from Ba¨rnighausen et al [13]; F. Cumulative number of people initiating treatment in the Hlabisa Treatment and
Care Programme, model versus unpublished data [16]; G. Cumulative distribution of CD4+ cell counts at first test, model compared to data for 2007
to 2009. Data derived from the Hlabisa Treatment and Care Programme [16]. H. Cumulative distribution of CD4+ cell counts after 1 year on ART,
model compared to data. Data derived from the Hlabisa Treatment and Care Programme [16].
doi:10.1371/journal.pone.0021919.g001
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converted all costs into US dollars using the average exchange rate
for January 2010 of US$1 to R 7.42 [26]. Costs in future years
were discounted at an annual rate of 3% [27].
Simulations
We predicted the impact of increasing the threshold for
treatment initiation to #350 cells/ml starting by mid 2010, versus
continuing with treatment initiation at #200 cells/ml, on HIV
epidemic dynamics, number of people on ART, and associated
annual costs for adults aged 15+ in the Hlabisa Treatment and
Care Program in Hlabisa subdistrict until 2040. We then
calculated the cumulative net costs and cumulative number of
life-years saved by starting treatment at higher CD4+ counts. To
roughly compare the new WHO strategy to the current South
African strategy, we also assumed a scenario that a fraction of 19%
of the patients with CD4+ cell counts of 201–350 cells/ml is
eligible for treatment in the #200 cells/ml scenario (see Supple-
mentary Material S1).
To correct for the stochasticity of the model, we used the
average result of 1000 runs. We also presented the results of 50
individual runs to visualize the variation in model predictions.
Each run was based on about 35,000 simulated individuals.
Absolute values (number of people on treatment, annual costs, and
life-years saved) were multiplied by 6.5 to represent the situation of
Hlabisa subdistrict, which has 228,000 inhabitants [16].
Sensitivity analysis and scenario analysis
We performed a univariate sensitivity analysis on all key
parameters. Our assumption that ART reduces infectiousness by
92% is based on the most recent evidence [7,21,22]. However,
others have assumed a reduction of 99% [28], while less reduction
has also been opted [29]. Therefore, we also ran the model using
reductions of 80% and 99% respectively. Dropout rates in the
Hlablisa subdistrict are relatively low (1.27% per year), likely due
to the experimental nature of the area. Therefore, we also assumed
a dropout rate of 10% per year, which is more representative for
the rest of South Africa [30], and a lower value of 1% per year.
Furthermore, we made predictions for a 10% higher and 10%
lower overall partner change rates (see Supplementary Material S1) to
reflect the results for different endemicity levels, where 10% lower
leads to an HIV prevalence close to that for South Africa as a
whole. All other parameters (health seeking rates, survival on
Figure 2. Projected impact of ART at CD4+ cell counts of #200 /ml (black) and the new WHO treatment guidelines of ART at CD4+
cell counts of #350 /ml (gray) on HIV epidemic dynamics in the Hlabisa subdistrict of the Umkhanyakunde District, KwaZulu/Natal,
South Africa, 1990–2040. A. HIV prevalence; B. HIV incidence; C. HIV mortality; D. Total number of people on ART. The results reflect the average
of 1000 model runs and concern adults ($15 years). The bar indicates the timing of the initial start of ART distribution in the first clinic (end 2004) till
full coverage of all 17 clinics in the area (mid 2010).
doi:10.1371/journal.pone.0021919.g002
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ART, ART costs, costs of dying, costs of not on ART) were varied
by a factor 2/3rd to determine the lower bound, and 3/2nd to
determine the upper bound.
We also performed a multivariate sensitivity analysis on 5
parameters related to the HIV epidemic and ART (overall partner
change rates, survival on ART, infectivity on ART, dropout rates,
and health seeking behavior rates). For each parameter we
randomly selected values from Weibull (for durations) or Beta
distributions (for proportions). The average of each distribution is
our point estimate, and 2.5% and 97.5% values represent the
lower and upper bounds chosen in the univariate sensitivity
analysis. We ran 1,000 randomly selected combinations of
parameters drawn from the distributions and used the 25th and
975th value to represent the bounds of the 95% confidence
interval over our main outcome.
Furthermore, we assumed 4 scenarios of foreseeable future
developments that could influence ART programs: (1) develop-
ment of more effective ART (99% reduction in infectiousness, and
increased survival by a factor 4 relative to ART naı¨ve HIV
patients); (2) further reduction in ART prices (reduced ART costs
by 20%); (3) risk compensation in response to reduced threat of
HIV(condom use of 10% in casual contacts); (4) resistance
development (increased ART costs by 20% due to more need of
second- and third-line treatment options). All scenarios are
assumed to take effect in 2015.
Results
Our model was able to accurately simulate the demographic
structure, sexual behavior dynamics, and HIV and STI prevalence
in the Hlabisa subdistrict both before and after the ART rollout in
2004 (figure 1). Two differences between model and data can be
seen. First, the model predicts about 25% more men in the 60+
age group than observed (figure 1A), possibly as a result of a higher
background mortality rate in this group compared to the Coale-
Demeney life table used. However, the contribution of this age
group to the overall HIV epidemic in the area is limited, so this
discrepancy will not affect our main results. Second, the reported
number of recent sexual partners of women is much lower than
predicted by the model (figure 1B). This is likely a result of
underreporting, something that is commonly observed in studies
on reported sexual risk behaviour [34–37]. The prevalence of
classic STIs, which is often viewed as a more accurate indicator of
risk behaviour, accurately fits the data for women (figure 1C). As a
consequence of the good fit of the underlying demography
(figure 1A), risk behavior (figure 1B) and co-factors (figure 1C), the
predicted HIV prevalence is very close to that observed, both over
time (within 0.3% to 0.9% between 2004 and 2009; figure 1D) and
within age and sex groups (figure 1E). Furthermore, the
cumulative number of people initiating treatment in the model
accurately reflects the actual treatment initiation numbers
observed in the program (figure 1F). Finally, the model accurately
fits CD4+ cell count distributions as observed in the Hlabisa
Treatment and Care Programme, both at the time of initial testing
(figure 1G) and one year after initiating ART (figure 1H).
Figure 2 indicates that continued initiation of ART at CD4+ cell
counts of #200 cells/ml will result in a modest decline of the HIV
epidemic over the coming years. After peaking at 24% in 2015,
HIV prevalence in adults (aged 15+) is predicted to reduce to 20%
in 2040 (figure 2A). Incidence will continuously decrease from 2.6/
100 person years in 2010 to 2.0/100 person years in 2040
(figure 2B). Although mortality rates were almost halved over the
period 2004–2009, which is consistent with observations [18], we
predict a rebound in 2010, associated with mortality in patients on
ART (figure 2C). We expect that by 2018 the number of people on
ART would have peaked at 11,000, up from 8,000 on treatment in
2010 (figure 2D). The new WHO guidelines of treating patients at
#350 cells will have a more substantial effect on the epidemic,
reducing prevalence to 14% and incidence to 1.5/100 person-
years in 2040. Although initially the number of people on ART
will peak at about 16,000 in 2018, it will rapidly decline to nearly
the same number on treatment in 2040 compared to treatment at
#200 cells/ml (figure 2D).
Figure 3. Projected cost of the ART treatment and care program in the Hlabisa subdistrict of the Umkhanyakunde District,
KwaZulu/Natal, South Africa, 2010–2040. A. Annual cost when ART is initiated at #200 cells/ml. B. Annual cost when ART is initiated at
#350 cells/m. All ART costs concern adults aged 15+ and are stratified by CD4+ cell count at initiation and number of years on ART.
doi:10.1371/journal.pone.0021919.g003
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Figures 3A and 3B show the annual costs of treating patients at
#200 cells/ml and #350 cells/ml respectively. Even though the
average number of people on ART during the first five years (2011
to 2015) is predicted to be 28% higher under the new guidelines
(14,000 versus 11,000, figure 2D), the average estimated annual
costs are only 7% higher (US$28.6 million versus $ 26.8 million).
This is because costs are mostly incurred by people initiating
treatment at #100 cells/ml, and under the new WHO guidelines
there will be significantly fewer people in this category (figure 3B in
red). We predict that annual costs of treating patients at
#350 cells/ml or #200 cells/ml will become equal in 2017
(figure 3), and the cumulative net costs will reach a break-even
point in 2026 (figure 4A). Thereafter putting people on ART
starting at CD4+ cell counts of #350 cells/ml will lead to net cost-
savings. This break-even point is subject to stochasticity in the
model and may be reached between 2020 and 2033 (gray lines in
figure 4). In addition to these cost-savings, the new WHO
treatment guidelines will yield about 160,000 life-years saved by
2040 (figure 4B).
These findings are not very sensitive to alternative assumptions
of key parameters (table 2). Changes in cost values have the highest
impact on the timing of the breakeven point, but this is limited to
only 7 years. The cumulative number of life-years saved is most
affected by changes in partner change rates. Similar changes in
commercial sex work visits and circumcision rates had less effect
on the cumulative number of life-years saved (results not shown).
Multivariate sensitivity analysis shows that the uncertainty around
our point estimate of the breakeven point ranges between 2023
Figure 4. Projected net cost and life-years saved of implementing the new WHO treatment guidelines (ART at CD4+ cell counts of
#350 /ml) versus the old treatment guidelines (ART at CD4+ cell counts of #200 cells/ml) in the Hlabisa subdistrict of the
Umkhanyakunde District, KwaZulu/Natal, South Africa, 2010–2040. A. Cumulative net cost of treating patients at #350 cells/ml compared
to #200 cells/ml. Negative values reflect net cost-savings. B. Cumulative number of life-years saved when treating patients at #350 cells/ml compared
to #200 cells/ml. The black continuous line shows the average of 1000 model runs. Grey lines represent 50 individual runs to illustrate the random
variation in model output. Both dotted black lines represent the results for increased and decreased levels of endemicity, when assuming a 10%
higher and 10% lower overall partner change rate respectively (see also figure 1D). The blue line represents the results of treating patients at
#350 cells/ml versus a strategy of treating patients at #200 cells/ml, together with 19% of patients that report with CD4+ of 201–350 cells/ml. This
19% is a crude estimation of the proportion of pregnant women and TB co-infected patients among HIV-patients with CD4+ of 201–350, who are
since recently eligible to receive ART under the current South African strategy.
doi:10.1371/journal.pone.0021919.g004
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and 2031 (table 2). Alternative scenarios of future developments
regarding availability of more effective ART, further reductions in
ART prices, risk compensation, and increased resistance develop-
ment in the near future also have limited impact on both the
timing of the breakeven point and the number of life-years saved
(table 2).
When comparing the new guidelines with the scenario that 19%
of HIV patients with CD4+ cell counts of 201–350 receive ART
Table 2. Sensitivity analysis and scenario analysis.
Parameter Value
Timing of breakeven
point
Cumulative number of life years
saved in 2040 ( x 1000)
Baseline - 2026 158
Univariate sensitivity analysis
Partner change rates*
Lower bound 10% decrease 2025 136
Upper bound 10% increase 2026 175
Dropout rates
Lower bound 1% per year 2026 160
Upper bound 10% per year 2027 138
Health seeking rates**
Lower bound Factor 2/3 2030 142
Upper bound Factor 3/2 2025 165
Infectivity while on ART
Lower bound 80% reduction 2029 162
Upper bound 99% reduction 2024 158
Survival on ART
Lower bound Factor 2/3 2026 155
Upper bound Factor 3/2 2026 156
ART costs***
Lower bound Factor 2/3 2018 N.A.
Upper bound Factor 3/2 2033 N.A.
Cost of dying
Lower bound Factor 2/3 2028 N.A.
Upper bound Factor 3/2 2025 N.A.
Cost not on ART
Lower bound Factor 2/3 2032 N.A.
Upper bound Factor 3/2 2018 N.A.
Discounting
Lower bound 1% 2026 N.A.
Upper bound 7% 2031 N.A.
Multivariate sensitivity analysis
Lower bound N.A. 2023 112
Upper bound N.A. 2031 181
Scenario analysis****
More effective ART infectiousness on ART reduced by 99%,
survival to 4 times ART-naı¨ve survival
2022 145
Further reduction in ART prices Reduce ART
costs by 20%
2022 N.A.
Risk compensation Condom use reduced to 10% 2027 168
Resistance development Increase ART
costs by 20%
2027 N.A.
Timingofthebreakevenpoint(year)andcumulativenumberoflife-yearssaved(x1000)oftreatingpatientsaccordingtothenewWHOguidelinescomparedto#200 cells/mlareshown.
The breakeven point shows when cumulative net cost savings will occur.
*Effects of 10% increase and decrease in partner change rates are displayed as dotted lines in figure 1D, 4A and 4B.
**Applied to all 5 health seeking rates (rh(1) to rh(5), see Supplementary Material S1.
***Applied to all cost values displayed in table1.
****All scenarios changes is the scenario analysis take effect in 2015.
N.A. = Not Affected.
doi:10.1371/journal.pone.0021919.t002
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(crudely reflecting the current South African policy of providing
ART to pregnant and TB co-infected HIV patients), our model
explorations show there will still be a break-even point around
2026 (blue line figure 4A). The number of life-years saved by 2040
will then be about 120,000 (blue line in figure 4B).
Discussion
We show that starting ART at #350 cells/ml, as recently
recommended by WHO [1], will lead to only a modest increase in
program costs, but significantly more patients on ART in this rural
setting of KwaZulu-Natal, South Africa. Compared to ART
initiation at #200 cells/ml, initiating ART according to the new
WHO guidelines will result in cumulative net cost-savings starting
around 2026. This break-even point is robust to alternative
assumptions in key parameter values. In addition to net cost-
savings, the new guidelines produce a substantial increase in
number of life-years saved as well as a more profound decrease in
HIV prevalence and incidence.
Our baseline predictions concerning the Hlablisa subdistrict
could be too optimistic for South Africa as a whole, where dropout
rates are higher [30], health seeking behavior is less [12], and
endemicity levels are slightly lower [12]. However, the sensitivity
analysis shows that these differences have a limited impact on the
timing of the breakeven point and the number of life-years saved
(table 2). This can be explained by the fact that we compare two
scenarios (ART at #200 cells/ml versus #350 cells/ml), which are
both largely affected in the same way, so that the comparison
between the two remains relatively unchanged. This demonstrates
that our main finding of limited initial investments with a
breakeven point within a limited time horizon is generalizable to
South Africa as a whole.
We realize that the comparative strategy of starting ART at
#200 cells/ml does not fully represent the current South African
policy, since very recently the country announced that pregnant
women and TB patients co-infected with HIV should initiate ART
at #350 cells/ml [2,3]. However, our model explorations show
that when including 19% (roughly the proportion of pregnant
women or TB co-infected) of the patients with CD4+ between
201–350 in the #200 scenario will lead to the same general
finding: i.e. modest initial frontloading needed to adhere to the
WHO guidelines of treating all with CD4+ #350 cells/ml,
resulting in net cost-savings around the year 2026. The initial
investments of expanding the program to include all patients with
CD4+ cell counts of 201–350 cells/ml are likely to be even less
than predicted by our model, because especially TB co-infected
patients require more additional care and thus are more expensive
than other HIV-infected patients. On the other hand, the
projected number of life-years saved in this comparison is
somewhat overestimated since ART for pregnant women is
beneficial for both the mother and her unborn child [38].
Our baseline calculations are based on the premise that
assumption will not change in the future, but it is conceivable
that there may be developments that would influence the
epidemiological and economic impact of ART. The development
of new, more effective ART and further reduced ART prices
might improve the distribution and effectiveness of ART [39],
while concerns exist regarding risk compensation [40] and
resistance development [41]. However, the scenario analysis
shows that each of these possible future developments has limited
impact on both the timing of the breakeven point and the number
of life years saved (table 2).
Thus, it is clear that from an economic point of view South
Africa should adopt the full WHO guidelines as soon as possible,
given the expected net savings within a limited time-horizon.
However, there are limitations regarding infrastructural and
human resources, which are already stretched under the current
efforts of South Africa to provide treatment and care for HIV-
infected patients [43,44]. This was also the reason why South
Africa decided not to adopt the full WHO guidelines. Infra-
structural expansion may require increased funding, resulting in
the postponement of the breakeven point. However, model
explorations show that, when adding 10% to the overall annual
costs in the first five years of treating patients according to the new
WHO guidelines in order to reflect the costs for infrastructural
expansion, net cost savings will occur only 6 years later (results not
shown). The expected savings achieved by adopting the full WHO
guidelines could be a basis to ensure sufficient resources for
infrastructural development and increase the pool of health
workers through task shifting, decentralization, increased training,
and higher salaries [43,45].
The effect of ART on HIV epidemic dynamics and costs has
been explored in a number of other modeling studies [21,28,46–
48]. However, our microsimulation model allows more accurate
modeling of sexual networks, transmission dynamics and STI co-
factor effects. It is striking that our model gives such a good
representation of the demographic and epidemiological situation
of this setting, while only three parameters (overall partner change
rate and two parameters for health seeking - see Supplementary
Material S1) were used to calibrate the model. Moreover, it is
reassuring that our model predicts a stable HIV incidence over the
period 2003–2007 (figure 2B), as reported by Ba¨rnighausen et al
[14] and the strong decline in HIV-related mortality during the
first years of ART rollout (figure 2C) is consistent with Herbst et al
[18].
In conclusion, our study provides a strong argument in favor of
immediately adopting the new WHO treatment guidelines, rather
than starting ART at #200 cells/ml, or only implementing the
guidelines for specific groups. This is provided that increased
efforts are undertaken to increase human resources and healthcare
infrastructure. In addition to a reduction in transmission and
mortality, and a substantial increase in life-years saved, cumulative
net cost-savings for treating patients with CD4+ cell counts of
#350 cells/ml will occur after about 16 years. We show that the
new WHO guidelines are beneficial from a financial, epidemio-
logical, and societal point of view, regardless of future develop-
ments, and South Africa should therefore aim at rapidly
expanding its healthcare infrastructure to fully embrace the new
WHO guidelines.
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